Table 1.
Variable | BC (n = 1806) | Variable | BC (n = 1806) |
---|---|---|---|
Age at diagnosis (years) | 62 ± 13 [26–95] | pN | |
BMI | 26.7 ± 25.5 [14.2-46.1] | 0 | 1204 (70.2%) |
Hormonal Status | 1 | 360 (21%) | |
Fertile | 439 (24.3%) | 2 | 88 (5.1%) |
Pregnancy | 2 (0.1%) | 3 | 63 (3.7%) |
Menopause | 1347 (74.6%) | Biological portrait | |
Replacement therapy | 18 (1%) | ER+/HER2- | 1368 (80.9%) |
Type of surgery | ER+/HER2+ | 144 (8.5%) | |
Conservative surgery | 1345 (74.5%) | ER-/HER2+ | 69 (4.1%) |
Mastectomy | 461 (25.5%) | ER-/HER2- | 110 (6.5%) |
Axillary dissection | PG | ||
No | 1180 (65.3%) | Negative | 384 (21.3%) |
Yes | 626 (34.7%) | Positive | 1422 (78.7%) |
LNS biopsy | Ki67 | ||
No | 316 (17.5%) | ≤ 14% | 1177 (65.2%) |
Yes | 1490 (82.5%) | > 14% | 629 (34.8%) |
Type of breast cancer | Radiotherapy | ||
Microinvasive | 27 (1.5%) | No | 504 (28.1%) |
Invasive | 1779 (98.5%) | Yes | 1288 (71.9%) |
Histological type | Chemotherapy | ||
Ductal | 1409 (78%) | No | 1218 (68.2%) |
Lobular | 278 (15.4%) | Yes | 567 (31.8%) |
Others | 119 (6.6%) | Biological therapy | |
Grading | No | 1487 (89.6%) | |
I | 190 (10.6%) | Yes | 173 (10.4%) |
II | 1133 (63.2%) | Hormonal therapy | |
III | 469 (26.2%) | No | 307 (17.2%) |
Lymphovascular invasion | Yes | 1476 (82.8%) | |
No | 1053 (58.6%) | Exitus | |
Yes | 744 (41.4%) | No | 1779 (98.0%) |
Tumor dimension (mm) | 15 ± 9 [0-100] | Yes | 37 (2.0%) |
pT | DM | ||
X | 7 (0.4%) | No | 1700 (94.1%) |
1 | 1468 (81.3%) | Yes | 106 (5.9%) |
2 | 305 (16.9%) | Time to DM (months) | 25 ± 25 [0-60] |
3 | 12 (0.6%) | LRR | |
4 | 14 (0.8%) | No | 1715 (92.6%) |
Yes | 91 (7.4%) | ||
Time to LRR (months) | 25 ± 25 [0-60] |
BC, breast cancer; BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PG, progesterone receptor; DM, distant metastasis; LRR, locoregional recurrence.
Data are expressed as mean ± standard deviation or total numbers; range and frequency distribution are shown within square and round parentheses, respectively.